Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

72.7%

8 terminated/withdrawn out of 11 trials

Success Rate

11.1%

-75.4% vs industry average

Late-Stage Pipeline

18%

2 trials in Phase 3/4

Results Transparency

700%

7 of 1 completed trials have results

Key Signals

7 with results7 terminated

Enrollment Performance

Analytics

Phase 1
4(44.4%)
Phase 2
3(33.3%)
Phase 3
2(22.2%)
9Total
Phase 1(4)
Phase 2(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT07559799Not Yet Recruiting

A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)

Role: collaborator

NCT03151811Phase 3Terminated

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Role: lead

NCT04649060Phase 3Terminated

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

Role: lead

NCT03639610Phase 2Terminated

PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function

Role: lead

NCT04412707Phase 2Terminated

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

Role: lead

NCT03481556Phase 1Terminated

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

Role: lead

NCT02963493Phase 2Completed

A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT04115956Phase 1Terminated

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Role: lead

NCT04918511Phase 1Withdrawn

A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma

Role: lead

NCT04534322Unknown

Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma

Role: lead

NCT01897714Phase 1Terminated

Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

Role: lead

All 11 trials loaded